Analysguiden publishes research report setting new price target of SEK 39 with an optimistic fair value of at least SEK 80
Hørsholm, Denmark, March 9, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Analysguiden has updated their research reports on ExpreS2ion in March, following the publication of year-end 2021 results, the release of additional positive Phase II COVID-19 results, and the announcement of the plan to initiate a regulatory validated Phase III trial within the first half of 2022 for the ABNCoV2 vaccine. Analysguiden set a new price target of SEK 39, based on a revised forecast of market size and price per dose, while acknowledging that a